Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Blog - Page 88

Blog

Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID
COVID-19 | Life Science History

Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID

On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…

Read More Axcella Therapeutics launched clinical program to develop treatment for patients with long COVIDContinue

Moderna announced Swissmedic authorized booster dose of Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced Swissmedic authorized booster dose of Moderna’s COVID-19 vaccine

On Oct. 26, 2021, Moderna announced that Swissmedic had authorized a booster dose of Spikevax, the Company’s vaccine…

Read More Moderna announced Swissmedic authorized booster dose of Moderna’s COVID-19 vaccineContinue

COVID-19 infection presents greater risk of causing very rare neurological events than vaccines
COVID-19 | Neurology

COVID-19 infection presents greater risk of causing very rare neurological events than vaccines

On Oct. 25, 2021, scientists at Oxford University reported that Infection with COVID-19 carried a much higher risk…

Read More COVID-19 infection presents greater risk of causing very rare neurological events than vaccinesContinue

European Commission selected Humanigenメs lenzilumab as one of the 10 most promising treatments for COVID-19
COVID-19 | Life Science History

European Commission selected Humanigenメs lenzilumab as one of the 10 most promising treatments for COVID-19

On Oct. 25, 2021, Humanigen announced the European Commission had identified lenzilumab as one of the モ10 most…

Read More European Commission selected Humanigenメs lenzilumab as one of the 10 most promising treatments for COVID-19Continue

Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European Union
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European Union

On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read More Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European UnionContinue

Merck and Ridgeback initiated rolling review by EMA for Molnupiravir, investigational oral antiviral medicine, for treatment of COVID-19
COVID-19 | Life Science History

Merck and Ridgeback initiated rolling review by EMA for Molnupiravir, investigational oral antiviral medicine, for treatment of COVID-19

On Oct. 25, 2021, Merck and Ridgeback Biotherapeutics announced the European Medicines Agency (EMA) had initiated a rolling…

Read More Merck and Ridgeback initiated rolling review by EMA for Molnupiravir, investigational oral antiviral medicine, for treatment of COVID-19Continue

Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of age
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of age

On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study,…

Read More Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of ageContinue

HHS invested over $560 million to bolster product manufacturing to increase supply, availability of COVID-19 tests
COVID-19 | Life Science History

HHS invested over $560 million to bolster product manufacturing to increase supply, availability of COVID-19 tests

On Oct. 22, 2021, the Department of Health and Human Services (HHS), announced that it had invested more…

Read More HHS invested over $560 million to bolster product manufacturing to increase supply, availability of COVID-19 testsContinue

The U.S. CDC reported two new variant Influenza (Flu) virus infections
Agriculture | Biotechnology | CDC | Diagnostics | Infectious Disease | Influenza | Veterinary

The U.S. CDC reported two new variant Influenza (Flu) virus infections

On Oct. 22, 2021, the U.S. Centers for Disease Control and Prevention (CDC) reported two new U.S. human…

Read More The U.S. CDC reported two new variant Influenza (Flu) virus infectionsContinue

The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees
Biotechnology | COVID-19 | Infectious Disease | Vaccine

The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees

On Oct. 22, 2021, the U.S. Department of Veterans Affairs (VA) announced that it had begun offering Moderna…

Read More The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employeesContinue

Ligand and CR Double-Crane entered agreement to develop oral COVID-19 therapeutic
COVID-19 | Life Science History

Ligand and CR Double-Crane entered agreement to develop oral COVID-19 therapeutic

On Oct. 21, 2021, Ligand Pharmaceuticals announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical…

Read More Ligand and CR Double-Crane entered agreement to develop oral COVID-19 therapeuticContinue

U.S. CDC Advisory Committee unanimously recommended Johnson &  Johnson COVID-19 vaccine as booster for all eligible individuals
CDC | COVID-19 | Life Science History

U.S. CDC Advisory Committee unanimously recommended Johnson & Johnson COVID-19 vaccine as booster for all eligible individuals

On Oct. 21, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Prevention (CDC)…

Read More U.S. CDC Advisory Committee unanimously recommended Johnson & Johnson COVID-19 vaccine as booster for all eligible individualsContinue

COVID-19 booster increased antibody responses, was protective in rhesus macaques
COVID-19 | Life Science History | Vaccine

COVID-19 booster increased antibody responses, was protective in rhesus macaques

On Oct. 21, 2021, the National Institutes of Health announced that a booster dose of the mRNA-1273 COVID-19…

Read More COVID-19 booster increased antibody responses, was protective in rhesus macaquesContinue

Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine

On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…

Read More Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccineContinue

INOVIO announced MOU with Colombia for protecting against COVID-19 and broader health initiatives
Biotechnology | COVID-19 | Life Science History | Vaccine

INOVIO announced MOU with Colombia for protecting against COVID-19 and broader health initiatives

On Oct. 21, 2021, Inovio Pharma announced the signing of a non-binding memorandum of understanding with Colombia’s Ministry…

Read More INOVIO announced MOU with Colombia for protecting against COVID-19 and broader health initiativesContinue

Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDA
COVID-19 | FDA | Life Science History

Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDA

On Oct. 20, 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) had issued Emergency…

Read More Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDAContinue

NIH launched program to map a rare type of non-dividing cells implicated in human health and disease
Life Science History | NIH

NIH launched program to map a rare type of non-dividing cells implicated in human health and disease

On Oct. 18, 2021, the National Institutes of Health launched a program to study a rare type of…

Read More NIH launched program to map a rare type of non-dividing cells implicated in human health and diseaseContinue

Moderna announced FDA authorization of booster dose of  COVID-19 vaccine in the U.S.
Biotechnology | COVID-19 | FDA | Infectious Disease

Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.

On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…

Read More Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.Continue

Quest Diagnostics provided K-12 School COVID-19 testing with Ginkgo Bioworks to support safer classrooms in Texas
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

Quest Diagnostics provided K-12 School COVID-19 testing with Ginkgo Bioworks to support safer classrooms in Texas

On Oct. 20, 2021, Quest Diagnostics announced it had formed an agreement with the Texas Department of State…

Read More Quest Diagnostics provided K-12 School COVID-19 testing with Ginkgo Bioworks to support safer classrooms in TexasContinue

Largest ever global study of tuberculosis identified genetic causes of drug resistance
Life Science History

Largest ever global study of tuberculosis identified genetic causes of drug resistance

On Oct. 19 , 2021, researchers at the University of Oxford, using cutting-edge genomic sequencing techniques, announced they…

Read More Largest ever global study of tuberculosis identified genetic causes of drug resistanceContinue

Study found that for the unvaccinated, reinfection by COVID-19 was likely
COVID-19 | Life Science History

Study found that for the unvaccinated, reinfection by COVID-19 was likely

On Oct. 19, 2021, National Science Foundation funded scientists at the Yale School of Public Health and the…

Read More Study found that for the unvaccinated, reinfection by COVID-19 was likelyContinue

NYU Langone Health’s Groundbreaking Transplant Offers Hope amid Organ Shortages
Biotechnology | Disease | Non-Profit Research | Therapeutics

NYU Langone Health’s Groundbreaking Transplant Offers Hope amid Organ Shortages

On Oct. 19, 2021, the first investigational transplant of a genetically engineered, nonhuman kidney to a human body…

Read More NYU Langone Health’s Groundbreaking Transplant Offers Hope amid Organ ShortagesContinue

Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19
COVID-19 | Life Science History

Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19

On Oct. 18, 2021, a NIAID sponsored clinical trial found that treatment with the immunomodulator interferon beta-1a plus…

Read More Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19Continue

COVID-19 vaccine developed by Valneva using Dynavax’s CpG 1018 adjuvant met co-primary endpoints in phase 3 trial
COVID-19 | Life Science History | Vaccine

COVID-19 vaccine developed by Valneva using Dynavax’s CpG 1018 adjuvant met co-primary endpoints in phase 3 trial

On Oct. 18, 2021, Dynavax Technologies announced that Valneva reported positive topline results from the Phase 3 pivotal…

Read More COVID-19 vaccine developed by Valneva using Dynavax’s CpG 1018 adjuvant met co-primary endpoints in phase 3 trialContinue

FDA approved naloxone injection to counteract opioid overdoses
FDA | Life Science History

FDA approved naloxone injection to counteract opioid overdoses

On Oct. 18, 2021, the Food and Drug Administration approved ZIMHI (naloxone hydrochloride) injection as an additional option…

Read More FDA approved naloxone injection to counteract opioid overdosesContinue

U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations
Biotechnology | FDA | HIV | Therapeutics

U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations

On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…

Read More U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populationsContinue

LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in children
Genomics | Life Science History

LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in children

On Oct. 18, 2021, LogicBio Therapeutics announced clinical trial results that demonstrated the first-ever in vivo genome editing…

Read More LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in childrenContinue

Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY

On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…

Read More Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATYContinue

Athenex and Center for Cell and Gene Therapy announced allowance of first U.S. patent around CAR-NKT cell therapy
Biotechnology | Non-Profit Research | Therapeutics

Athenex and Center for Cell and Gene Therapy announced allowance of first U.S. patent around CAR-NKT cell therapy

On Oct. 18, 2021, Athenex and the Center for Cell and Gene Therapy at Baylor College of Medicine,…

Read More Athenex and Center for Cell and Gene Therapy announced allowance of first U.S. patent around CAR-NKT cell therapyContinue

Relief’s collaboration partner published positive aviptadil data in high comorbidity critical COVID-19 patients
COVID-19 | Life Science History

Relief’s collaboration partner published positive aviptadil data in high comorbidity critical COVID-19 patients

On Oct. 15, 2021, RELIEF THERAPEUTICS reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals,…

Read More Relief’s collaboration partner published positive aviptadil data in high comorbidity critical COVID-19 patientsContinue

Page navigation

Previous PagePrevious 1 … 86 87 88 89 90 … 362 Next PageNext
  • Categories
  • Timeline
  • Aesthetics
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemistry
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Quantum
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Banner Advertising

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search